Hackert, Thilo

Neoadjuvant therapy for pancreatic cancer

Springfeld, C., Ferrone, C. R., Katz, M. H. G., Philip, P. A., Hong, T. S., Hackert, T., Büchler, M. W., & Neoptolemos, J. (2023) · Nature Reviews Clinical Oncology

Pancreatic and Hepatic Oncology ResearchCholangiocarcinoma and Gallbladder Cancer Studies

Cited by 377

Toward the blood-borne miRNome of human diseases

Keller, A., Leidinger, P., Bauer, A., ElSharawy, A., Haas, J., Backes, C., Wendschlag, A., Giese, N., Tjaden, C., Ott, K., et al. (2011) · Nature Methods

MicroRNA in disease regulationGene expression and cancer classification

Cited by 355

Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer

Klein, A. P., Wolpin, B. M., Risch, H. A., Stolzenberg-Solomon, R. Z., Mocci, E., Zhang, M., Canzian, F., Childs, E. J., Hoskins, J. W., Jermusyk, A., et al. (2018) · Nature Communications

Pancreatic and Hepatic Oncology ResearchGenetic Associations and Epidemiology

Cited by 268

European Guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendations

Löhr, J., Beuers, U., Vujasinovic, M., Alvaro, D., Frøkjær, J. B., Buttgereit, F., Capurso, G., Culver, E. L., de‐Madaria, E., Della‐Torre, E., et al. (2020) · United European Gastroenterology Journal

IgG4-Related and Inflammatory DiseasesPancreatitis Pathology and Treatment

Cited by 252

Cachectic Body Composition and Inflammatory Markers Portend a Poor Prognosis in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiation

Naumann, P., Eberlein, J., Farnia, B., Liermann, J., Hackert, T., Debus, J., & Combs, S. E. (2019) · Cancers

Nutrition and Health in AgingPancreatic and Hepatic Oncology Research

Cited by 54

Cytologic analysis of pancreatic juice increases specificity of detection of malignant IPMN—a systematic review

Tanaka, M., Heckler, M., Liu, B., Heger, U., Hackert, T., & Michalski, C. W. (2019) · Clinical Gastroenterology and Hepatology

Pancreatic and Hepatic Oncology ResearchNeuroendocrine Tumor Research Advances

Cited by 36

Pancreatic resection with perioperative drug repurposing of propranolol and etodolac – the phase II randomized controlled PROSPER trial

Hüttner, F. J., Klotz, R., Giese, N. A., Kong, B., Ahmed, A., Merz, D., Pöchmann, A., Burghaus, I., Hackert, T., Strobel, O., et al. (2025) · Langenbeck's Archives of Surgery

Cancer, Stress, Anesthesia, and Immune ResponsePancreatic and Hepatic Oncology Research

Cited by 15

Pancreatic resection with perioperative drug repurposing of propranolol and etodolac: trial protocol of the phase-II randomised placebo controlled PROSPER trial

Hüttner, F. J., Rooman, I., Bouche, G., Knebel, P., Hüsing, J., Mihaljevic, A. L., Hackert, T., Strobel, O., Büchler, M. W., & Diener, M. K. (2020) · BMJ Open

Cancer, Stress, Anesthesia, and Immune ResponsePancreatic and Hepatic Oncology Research

Cited by 13

Influence of beta-blockers and other non-cancer drugs on outcomes after pancreatic cancer resection

Hüttner, F. J., Mauch, M., Heckler, M., Hackert, T., Büchler, M. W., Probst, P., & Diener, M. K. (2023) · British Journal of Surgery

Pancreatic and Hepatic Oncology ResearchCancer, Stress, Anesthesia, and Immune Response

Cited by 7